ReviewJournal of clinical hypertension (Greenwich, Conn.)2025
The Association Between the Hemoglobin Glycation Index and Cardiometabolic Diseases: A Mini-Review.
Review in Journal of clinical hypertension (Greenwich, Conn.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- Glycation at the Crossroads of Disease Pathogenesis: Mechanistic Insights and Therapeutic Frontiers.Diseases (Basel, Switzerland) · 2026Review
- Relationship between hemoglobin glycation index and mild cognitive impairment risk in middle-aged and elderly people: a cohort study from CHARLS 2011-2018.Frontiers in neurology · 2026Article
- Association Between Thyroid Hormone Sensitivity and Non-Alcoholic Fatty Liver Disease in Individuals with Normal Thyroid Function.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Comment on: "Association Between the Hemoglobin Glycation Index (HGI) and Risk of Diabetic Nephropathy: A Retrospective Cohort Study" [Response to Letter].Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The hemoglobin glycation index (HGI) has emerged as a pivotal biomarker for evaluating long-term glycemic control, offering a more comprehensive assessment compared with conventional glycated hemoglobin (HbA1c) measurements. Elevated HGI levels are significantly correlated with the incidence of cardiometabolic diseases (CMDs). This review synthesizes current evidence on the clinical utility of the HGI across coronary artery disease (CAD), hypertension, heart failure (HF), diabetes mellitus (DM), serum uric acid (SUA) levels, and nonalcoholic fatty liver disease (NAFLD), thereby providing clinicians with an enhanced framework for precise disease stratification, therapeutic optimization, and prognostic prediction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.